No deals are currently on the calendar for the week ahead, although some small deals may join the calendar throughout the week, as the typical February lull takes hold of the IPO market while issuers work on year-end audited financials. While recent IPO...read more
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
Two sizable IPOs priced this week, joined by seven SPACs. Ten IPOs and eight SPACs submitted initial filings. Medical supplies giant Medline (MDLN) priced its upsized IPO above the midpoint to raise $6.3 billion at a $38.7 billion market cap. The company is ...read more
US IPO Week Ahead: February set to end on a quiet note
No deals are currently on the calendar for the week ahead, although some small deals may join the calendar throughout the week, as the typical February lull takes hold of the IPO market while issuers work on year-end audited financials. While recent IPO...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
US IPO Weekly Recap: Medline and Andersen soar ahead of Christmas holiday
Two sizable IPOs priced this week, joined by seven SPACs. Ten IPOs and eight SPACs submitted initial filings. Medical supplies giant Medline (MDLN) priced its upsized IPO above the midpoint to raise $6.3 billion at a $38.7 billion market cap. The company is ...read more